GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (STU:23I) » Definitions » Volatility

Intra-Cellular Therapies (STU:23I) Volatility : 33.21% (As of Dec. 14, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Intra-Cellular Therapies Volatility?

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2024-12-14), Intra-Cellular Therapies's Volatility is 33.21%.


Competitive Comparison of Intra-Cellular Therapies's Volatility

For the Drug Manufacturers - Specialty & Generic subindustry, Intra-Cellular Therapies's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intra-Cellular Therapies's Volatility Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Intra-Cellular Therapies's Volatility distribution charts can be found below:

* The bar in red indicates where Intra-Cellular Therapies's Volatility falls into.



Intra-Cellular Therapies  (STU:23I) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intra-Cellular Therapies  (STU:23I) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


Intra-Cellular Therapies Volatility Related Terms

Thank you for viewing the detailed overview of Intra-Cellular Therapies's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.


Intra-Cellular Therapies Business Description

Traded in Other Exchanges
Address
430 East 29th Street, New York, NY, USA, 10016
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Intra-Cellular Therapies Headlines

No Headlines